Who Is Funding Your Paraquat Case? Why the Judge's October Disclosure Orders Matter to Every Claimant Still Deciding

In October 2026, the judge overseeing the federal paraquat litigation ordered a plaintiffs' lawyer to disclose any outside funding behind hundreds of cases, then extended the same inquiry to a second lawyer. The orders ask a blunt question: are settlement rejections the clients' own informed decisions, or someone else's?

Key Facts

  • 6,602 paraquat actions were pending in MDL No. 3004 on October 1, 2026, out of 8,495 filed since consolidation.
  • October 14, 2026: the judge ordered R. Allen Smith to disclose outside funding for his 750 clients, only 49 of whom were participating in the proposed settlement.
  • Within 14 days, Smith was also ordered to produce his opt-out clients' plaintiff fact sheets and set their depositions.
  • October 21, 2026: the court extended the inquiry, ordering a second lawyer to explain why his clients are not participating in the proposed settlement.
  • The master settlement agreement was signed on September 3, 2025, but its terms are confidential and no public payment schedule exists.

Paraquat is a herbicide, a weed-killing chemical, whose federal lawsuits allege that exposure increased the risk of Parkinson's disease, a progressive disorder of movement. A multidistrict litigation, usually shortened to MDL, is a procedure that groups similar federal cases before one judge for pretrial work while each case stays individual.

The Order That Started It: October 14

The federal paraquat cases are consolidated as MDL No. 3004 before Chief Judge Nancy J. Rosenstengel in the Southern District of Illinois. On October 14, 2026, she ordered R. Allen Smith of The Smith Law Firm to disclose any outside funding he may be receiving in cases filed for his 750 clients. Her stated concern, in her own words, was to be sure that the decisions to reject the proposed settlement were made by the right people, meaning the clients themselves, fully informed. Only 49 of Smith's 750 clients were participating in the proposed settlement, leaving roughly 700 who had opted out. Alongside the disclosure order, she directed Smith to attend fortnightly court conferences so she can speak to each of those clients directly, and to produce their plaintiff fact sheets within 14 days and set their depositions. A plaintiff fact sheet is a standardized form setting out the basics of a claim: exposure, diagnosis, and medical history. The order was not a finding that funding existed or that anything improper happened; it was a demand for transparency before the court trusts the rejection numbers.

October 21: The Inquiry Widens to a Second Lawyer

A week later, the inquiry widened. On October 21, 2026, the court ordered a second lawyer to explain why his clients are not participating in the proposed settlement, with financing disclosures again at the center of the discussion. The widening matters because the pattern was never confined to one firm. Back in June 2026, alarmed at what she called exceedingly high opt-out rates, the judge had already ordered three firms to complete depositions within 60 days for a sample of their cases, 74 in total. At an August 27 hearing she told another firm's lawyer that she had serious concerns about why all of his clients had opted out. Reporting on the settlement's reception put the scale in perspective: at least three firms reported refusal rates of 80% or higher, one firm's clients rejected at a rate reported as 100%, and 183 of 217 clients of a third firm refused. The October orders therefore test a system-wide question, not a single lawyer's practice: when rejections cluster this tightly by firm, are they the product of informed clients, or of advice, paperwork, or financing arrangements the clients never saw?

Why Funding Disclosure Changes the Settlement Math

Third-party funding does not automatically taint a case. Funders bankroll expensive litigation that individual claimants could never afford, and many funded cases are entirely legitimate. The court's interest is narrower and more practical. If a funder is paid from any recovery, or if its agreement constrains settlement decisions, then a client's freedom to accept a fair offer may be narrower than it looks on paper. Disclosure lets the judge, and the client, see the full picture: who gets paid, how much, and whether any term discourages settlement. It also protects the settlement itself. A deal built on uninformed rejections invites later challenges, while a deal that survives direct conversations with hundreds of clients is far harder to attack. That is why the judge paired disclosure with face-to-face conferences rather than ordering disclosure alone. Compensation varies widely by case, and most settlements are confidential; the paraquat master settlement agreement, signed on September 3, 2025, follows that pattern, with no public payment schedule and no published payout grid.

Where the Litigation Stands Now

The backdrop explains the urgency. The parties announced a settlement framework in April 2025 and signed the master agreement on September 3, 2025; a qualified settlement fund, the vehicle that would administer payments, was set in motion with a March 2026 court filing, and the special master overseeing it gained access to settlement information in April 2026. Yet as of October 2026 no final global resolution had been announced, and trial activity remained paused while the settlement process moved. The first federal test cases never reached a jury: they were dismissed in April 2024 after the court excluded the plaintiffs' general-causation expert. A separate California case, Anderson v. Syngenta, is scheduled for trial on March 1, 2027, which would be the first paraquat case before a jury if it proceeds. Meanwhile the Supreme Court's June 25, 2026 ruling in Monsanto v. Durnell held that federal pesticide law can preempt state failure-to-warn claims, unsettling one of the central theories in paraquat cases and giving every claimant another reason to get current advice. Readers who want plain-language explainers on related legal and money topics can visit the Problem Solved channel.

Who Benefits From This — and Who Does Not

Claimants still deciding on the proposed settlement benefit first, because the disclosure orders give them questions they can ask their own lawyer today: is anyone funding my case, what are they paid, and did that affect the advice I received? Claimants with documented exposure and a confirmed Parkinson's diagnosis benefit second, since a docket cleaned of uninformed rejections and missing fact sheets is easier to settle or try. Families helping an elderly or ill relative benefit third, because the judge's insistence on hearing from clients directly protects relatives who may not have understood the offer. People who do not benefit include claimants with no documented exposure or no diagnosis, since disclosure cannot create proof, and claimants in state-court cases outside the federal MDL, which these federal orders do not govern. The earlier account of the 700 holdouts and the analysis of why plaintiffs walked away show the same dispute from the clients' side; the disclosure orders are the court's answer to it. And the ruling on the Supreme Court's preemption decision remains essential reading for anyone weighing trial against settlement now.

What to Do While the Disclosure Fight Plays Out

Do not treat the disclosure orders as a verdict on your case, and do not treat silence as safety. Ask your lawyer, in writing, whether any funder holds an interest in your claim and what that interest pays. Confirm that you personally received the settlement terms and understood the deadline that applies to you, since registration and filing deadlines run on different clocks. Assemble the exposure file now: work records, applicator logs, purchase receipts, or employer statements, plus the diagnosis record and treatment history. If your case is among those headed for a fact-sheet or deposition order, treat that paperwork as the claim itself, because missing sheets and uncertain exposure were the very deficiencies the judge cited in August. Above all, decide on advice about your own file, not on headlines about other firms' clients.

Frequently Asked Questions

Who benefits from the judge's funding-disclosure orders?

Claimants deciding whether to accept the proposed settlement benefit most, because the orders test whether their rejection was truly informed. Claimants with strong exposure and diagnosis proof also benefit: a cleaner, better-documented docket makes their cases easier to value and harder to dismiss as paperwork.

Who does not benefit, or for whom are these orders not enough on their own?

Claimants who have not yet documented their paraquat exposure or their Parkinson's diagnosis do not benefit from disclosure orders alone, since disclosure does not supply missing proof. People whose cases sit in state courts outside the federal MDL are also not directly covered by these federal orders, and no disclosure order creates a payment or guarantees any amount.

How do I benefit, and how do I start if I am still deciding?

Start with four concrete steps. First, ask your lawyer in writing whether any outside funder has an interest in your case and what it is paid. Second, confirm you received and understood the actual settlement terms offered to you. Third, gather your exposure records, such as work logs, purchase records, or employer affidavits, and your diagnosis records. Fourth, compare the settlement path against the trial path, including the March 2027 California trial date, before any deadline that applies to you passes.

What is third-party litigation funding?

Third-party litigation funding is money supplied by an outside investor, not by the claimant or the lawyer, to finance a lawsuit, usually in exchange for a share of any recovery. Courts ask about it when they worry it could influence decisions that should belong to the client alone.

Why does the judge care how many clients rejected the settlement?

Because the rejections are concentrated: one firm's participation rate was about 49 of 750 clients, another firm's clients rejected at a rate reported as 100%, and 183 of 217 clients of a third firm refused. Concentration like that raises the question whether clients were fully informed, which is why the court ordered depositions, fact sheets, and direct conferences with the clients themselves.

Has any paraquat case reached a jury verdict?

No. The first federal test cases were dismissed in April 2024 after the court excluded the plaintiffs' general-causation expert, and no paraquat case has produced a jury verdict since. A California case is scheduled for trial on March 1, 2027, which would be the first if it proceeds.

This article is general information only and is not legal or medical advice. Litigation deadlines, settlement eligibility, and medical questions depend on individual facts; consult a qualified lawyer and your treating physician about your own situation.

Watch on YouTube

Problem Solved on YouTube